Literature DB >> 31251693

Reply to E. Hindié et al.

Roisin M Connolly1, Chiung-Yu Huang1, Vered Stearns1, Richard L Wahl1.   

Abstract

Year:  2019        PMID： 31251693      PMCID： PMC6879311          DOI： 10.1200/JCO.19.01078

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Interim [18F]Fluorodeoxyglucose-Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Authors:  Elif Hindié; David Groheux
Journal:  J Clin Oncol       Date:  2019-06-28       Impact factor: 44.544

2.  Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

Authors:  Bruno Coudert; Jean-Yves Pierga; Marie-Ange Mouret-Reynier; Kaldoun Kerrou; Jean-Marc Ferrero; Thierry Petit; Pierre Kerbrat; Pierre-François Dupré; Thomas Bachelot; Philippe Gabelle; Sylvia Giard; David Coeffic; Philippe Bougnoux; Jean-Briac Prevost; Gilles Paintaud; Gilles Thibault; Juana Hernandez; Mathieu Coudert; Laurent Arnould; Alina Berriolo-Riedinger
Journal:  Lancet Oncol       Date:  2014-10-30       Impact factor: 41.316

3.  TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.

Authors:  Roisin M Connolly; Jeffrey P Leal; Matthew P Goetz; Zhe Zhang; Xian C Zhou; Lisa K Jacobs; Joyce Mhlanga; Joo H O; John Carpenter; Anna Maria Storniolo; Stanley Watkins; John H Fetting; Robert S Miller; Kostandinos Sideras; Stacie C Jeter; Bridget Walsh; Penny Powers; Jane Zorzi; Judy C Boughey; Nancy E Davidson; Lisa A Carey; Antonio C Wolff; Nagi Khouri; Edward Gabrielson; Richard L Wahl; Vered Stearns
Journal:  J Nucl Med       Date:  2014-12-04       Impact factor: 10.057

4.  TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.

Authors:  Roisin M Connolly; Jeffrey P Leal; Lilja Solnes; Chiung-Yu Huang; Ashley Carpenter; Katy Gaffney; Vandana Abramson; Lisa A Carey; Minetta C Liu; Mothaffar Rimawi; Jennifer Specht; Anna Maria Storniolo; Vicente Valero; Christos Vaklavas; Ian E Krop; Eric P Winer; Melissa Camp; Robert S Miller; Antonio C Wolff; Ashley Cimino-Mathews; Ben H Park; Richard L Wahl; Vered Stearns
Journal:  J Clin Oncol       Date:  2019-02-05       Impact factor: 44.544

5.  18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.

Authors:  Geraldine Gebhart; Cristina Gámez; Eileen Holmes; Javier Robles; Camilo Garcia; Montserrat Cortés; Evandro de Azambuja; Karine Fauria; Veerle Van Dooren; Gursel Aktan; Maria Antonia Coccia-Portugal; Sung-Bae Kim; Peter Vuylsteke; Hervé Cure; Holger Eidtmann; José Baselga; Martine Piccart; Patrick Flamen; Serena Di Cosimo
Journal:  J Nucl Med       Date:  2013-10-03       Impact factor: 10.057
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.